HUYA Bioscience International LLC announced that it has exclusively licensed worldwide rights to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide is an investigational cancer compound, an orally bioavailable histone deacetylase (HDAC) inhibitor derived from the benzamide class and is currently approved to initiate a Phase I clinical trial in China.

Histone deacetylase inhibitors are a new class of cancer drugs that induce selective regulation of gene expression in cancer cells. Chidamide has exhibited preclinical efficacy and pharmacokinetic properties that may translate into a superior clinical profile over other HDAC inhibitors currently in development.

HUYA will co-develop chidamide with Chipscreen through Phase I clinical trials to be initiated shortly in China. Thereafter, HUYA plans to file an Investigational New Drug application and commence clinical trials of chidamide/HBI-8000 in the United States and Europe. Financial terms of the transaction were not disclosed.

About HUYA Bioscience International LLC

HUYA Bioscience International LLC, with offices in San Diego and Shanghai, capitalizes on the explosive growth of the biotechnology industry in China. HUYA identifies and licenses promising Chinese pharmaceuticals for commercialization in Western markets. Using its management team and advisors, HUYA lowers the product development risk through the comprehensive sourcing of proprietary preclinical and early clinical stage pharmaceuticals from China. HUYA partners the development of such innovative investigational pharmaceuticals with biotech companies in China so that the initial clinical research is performed in China. Later clinical development is expected to be completed in the United States and Europe.

About Shenzhen Chipscreen Biosciences Ltd

Shenzhen Chipscreen Biosciences Ltd is a leading China-based life sciences company that specializes in discovering and developing proprietary small molecule therapeutics, particularly in the area of receptor signaling. The company also provides a full suite of service solutions for the life sciences industry worldwide. Central to Chipscreen’s drug discovery platform are the company’s core capabilities including integration of in silico design, high content screening, pathway expression profiling, PK/PD screening, and informatics in the early stages of the discovery process. Chipscreen has increased the efficiency and accelerated the discovery of new medicines through its proprietary chemical genomics-based approach. Chipscreen operates its business from a state-of-the-art facility in Shenzhen, China, which is equipped with the latest computational and medicinal chemistry.
Contact Details:
HUYA Bioscience International LLC
Address: Shanghai Zhangjiang,
Hi-Tech Park,
780 Cailun Road,
China
Tel: +86 21 5132 3312
Email: info@huyabio.com
URL: www.huyabio.com

Contact Details:
Shenzhen Chipscreen Biosciences Ltd
Address: Research Institute of Tsinghua University,
High-Tech Park, Nanshan District,
Shenzhen, Guangdong Province,
China 518057
Tel: + 86 755 26957317
Fax: +86 755 26957291
Email: info@Chipscreen.com
URL: www.Chipscreen.com